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Objectives Our aim was to access clinical effectiveness of percutaneous coronary intervention (PCI) when added to optimal
medical therapy (OMT) in older patients with stable coronary artery disease (CAD).
Background While older patients with CAD are at increased risk for cardiac events compared with younger patients, it is un-
clear whether PCI may mitigate this risk more effectively than OMT alone or, alternatively, may be associated
with more complications.
Methods We conducted a pre-specified analysis of outcomes in stable CAD patients stratified by age and randomized to
PCI  OMT or OMT alone in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive druG
Evaluation) trial.
Results A total of 1,381 patients (60%) were 65 years of age (mean 56  6 years) and 904 patients (40%) were 65
years of age (mean 72  5 years). Achieved treatment targets for blood pressure, low-density lipoprotein choles-
terol, adherence to diet and exercise, and angina-free status did not differ by age or treatment assignment.
Among older patients, there was a 2- to 3-fold higher death rate, but similar rates of myocardial infarction,
stroke, and major cardiac events compared with younger patients. The addition of PCI to OMT did not improve or
worsen clinical outcomes in patients 65 years of age during a median 4.6 year follow-up.
Conclusions These data support adherence to American College of Cardiology/American Heart Association clinical practice guide-
lines that advocate OMT as an appropriate initial management strategy, regardless of age. (Clinical Outcomes Utiliz-
ing Revascularization and Aggressive Drug Evaluation [COURAGE]; NCT00007657) (J Am Coll Cardiol 2009;54:
1303–8) © 2009 by the American College of Cardiology Foundation
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The COURAGE Trial Outcomes by Age September 29, 2009:1303–8The management of older pa-
tients with coronary artery dis-
ease (CAD) is challenging since
the risk and benefits of treat-
ments are high and influenced by
comorbidities. Older patients
with acute coronary syndromes
(ACS) are at higher risk for car-
diac events than younger patients
and, although therapies may pro-
vide proportionately greater ben-
efit among patients at highest
risk (1,2), such patients with ad-
vanced age are often subject to a
“treatment-risk paradox” since
they tend to receive less evidence-
based secondary prevention than
younger, low-risk patients (3).
hether a disparity in treatment and outcomes exists in
lder patients with stable CAD who receive optimal med-
cal therapy (OMT) with or without percutaneous coronary
ntervention (PCI) remains uncertain. While age dichoto-
ized at 65 years was 1 of 8 pre-specified covariates in the
OURAGE (Clinical Outcomes Utilizing Revasculariza-
ion and Aggressive druG Evaluation) trial that did not
how a difference between PCI and OMT for the primary
nd point (death or myocardial infarction [MI]) during
ong-term follow-up, other important cardiovascular out-
omes that could vary by treatment assignment in older
ersus younger patients were not previously reported.
ethods
he design and main results of the COURAGE trial that
andomized 2,287 patients with stable CAD to PCI plus
MT versus OMT alone have been published (4–6). In the
resent study, we performed a post hoc analysis of baseline
haracteristics, achieved treatment targets at 60 months of
ollow-up, and pre-specified cardiovascular outcomes dur-
ng a 2.5- to 7-year (median 4.6-year) follow-up among
atients age 65 versus 65 years at baseline. Outcomes
or each age category were further subdivided by random-
zation status. Outcomes evaluated included the primary
fficacy measure of all-cause mortality or nonfatal MI (time
o first event); death; hospitalization for ACS; the compos-
.S. Department of Veterans Affairs. Dr. Teo has received honoraria from Boehr-
nger Ingelheim. Dr. Spertus has received grants from Bristol-Myers Squibb/Sanofi,
mgen, Lilly, and Johnson & Johnson; has served on the scientific advisory board for
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Abbreviations
and Acronyms
ACC  American College of
Cardiology
ACS  acute coronary
syndromes
AHA  American Heart
Association
BMI  body mass index
CAD  coronary artery
disease
MI  myocardial infarction
OMT  optimal medical
therapy
PCI  percutaneous
coronary interventionw
Manuscript received April 24, 2009; revised manuscript received July 8, 2009,
ccepted July 13, 2009.te of death, MI, or stroke; and the composite of death, MI,
troke, or hospitalization for ACS. Additional outcomes
ncluded the percentage of patients who achieved the target
or blood pressure, low-density lipoprotein cholesterol, body
ass index (BMI), smoking cessation, adherence to diet,
xercise, and medications, as well as angina-free status.
tatistical analysis. All statistical analyses were performed
sing the intent-to-treat principle. Data are expressed as
umbers and percents, mean  SD, and where appropriate,
s medians and interquartile ranges. Chi-square tests were
sed to compare categorical variables, while the Student
test or median test was used for continuous variables.
umulative event rates were estimated by the Kaplan-Meier
ethod, and treatment effects were assessed using the
tratified log-rank statistic (7). The Cox proportional hazards
odel (8) was used to estimate the hazard ratios and confi-
ence limits for the primary and secondary outcomes as well as
he interaction between treatment and age for these clinical
utcomes. For lifestyle outcomes, a generalized linear model
as used to assess the treatment and age effects and interaction
etween them (9). A level of significance of 0.01 was used for
ll statistical interactions and subgroup comparisons.
esults
aseline characteristics, by age, are shown in Table 1. There
ere 1,381 patients in the younger group (mean age 56  6
ears) and 904 patients in the older group (mean age 72 
years). Within each age group, there were no differences in
aseline characteristics between the randomized treatment
ssignment groups (Table 2). Procedural characteristics and
utcomes among patients randomized to PCI are shown in
able 3 and were similar for both age groups. Primary and
econdary outcomes are shown in Table 4. Among older
atients, there was a higher incidence of death or MI (p 
.001) and a 2- to 3-fold higher death rate (p  0.001) but
imilar rates of MI, stroke, and hospitalization for unstable
ngina compared with younger patients. However, there
as no interaction between age and the initial treatment
trategy assignment for any pre-specified clinical outcome.
Treatment targets achieved at 60 months of follow-up are
hown in Table 5. More younger patients than older
atients achieved the target systolic blood pressure 130
m Hg. There were comparably high rates of achieving the
arget low-density lipoprotein 85 mg/dl in older patients
78% of OMT patients; 70% of PCI  OMT patients) as
n the age65 years group (69% of OMT patients and 66%
f PCI  OMT patients). Achievement of targets at 60
onths for smoking cessation, adherence to American
eart Association (AHA) step II diet, exercise, and BMI
re summarized in Table 5. More older patients than
ounger patients achieved target BMI, which may relate
ore to age-related loss of skeletal muscle mass than to an
ncreased adherence to diet and/or exercise.
The percentage of patients in the younger group who
ere angina-free at 60 months of follow-up was 70% in
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September 29, 2009:1303–8 The COURAGE Trial Outcomes by Ageoth the OMT and PCI  OMT arms, whereas the
ercentage of angina-free patients in the older group was
ven higher, with 73% in the OMT arm and 80% in the
CI  OMT arm. Thus, despite the 2- to 3-fold higher
ate of death and a 50% higher rate of death, MI, or stroke
n the older patients, there was no evidence that PCI, when
dded to OMT, mitigated this risk, nor was PCI any more
ffective in achieving angina-free status in older patients.
owever, in older patients where age-related comorbidities
ay pose a higher risk for diagnostic coronary angiography
nd PCI, there were, likewise, no significant excess event
ates noted in the PCI  OMT versus OMT alone groups.
iscussion
n this pre-specified analysis of clinical outcomes by age from
he COURAGE trial, we found an overall 2- to 3-fold higher
aseline Characteristics Between Age GroupsTable 1 Baseline Characteristics Between Age Groups
Overall
(n  2,285)
Demographics
Sex: male 1,947 (85)
Race: white 1,963 (860)
Risk factor
Current smoker 653 (29)
Diabetic patient 766 (35)
Hypertension 1,521 (67)
Family history of CAD 1,093
Cardiac history
MI 876
PCI 359
CABG 248
CVD 202
CHF 108
Angiographic
Low EF 393
EF 61 11
1 VD 704
2 VD 885
3 VD 696
Physical
BMI 30 5
SBP 132 20
DBP 74 11
Angina*
Duration (months) 5 (1, 15)
Episodes/week 3 (1, 7)
Laboratory values*
Total cholesterol 174 (149, 200)
HDL 39 (33, 47)
LDL 101 (81, 124)
Triglycerides 146 (104, 210)
GFR 78 (66, 91)
alues are n (%) or mean  SD. *Median and interquartile range is shown for angina and laborat
BMI  body mass index; CABG  coronary artery bypass grafting; CAD  coronary artery diseas
jection fraction; GFR glomerular filtration rate; HDL high-density lipoprotein; LDL low-densit
ressure; VD  vessel disease.ncidence of death in patients65 years of age compared with patients 65 years of age but similar rates of MI, stroke, or
ospitalization due to ACS in both age groups. There was no
vidence that the addition of PCI to OMT was better (or worse)
han OMT alone in reducing clinical events. In addition, older
atients were angina-free at 60 months of follow-up with similar
ates for those treated with PCI (80%) and OMT (73%).
While PCI has been shown to have significant benefits in
he treatment of patients with ACS, notably by reducing
eath or MI during long-term follow-up, its role in the
anagement of stable CAD remains less certain. Although
CI of stenotic coronary arteries relieves symptoms of
ngina more effectively than medical management alone, it
oes not prevent “hard” clinical outcomes such as death or
I in stable CAD patients (10), yet it remains one of the
ost commonly performed procedures in such patients, and
ccounts for approximately one-third to one-half of all PCIs
e <65 Yrs
 1,381)
Age >65 Yrs
(n  904) p Value
7 (87) 750 (83) 0.01
3 (86) 780 (86) 0.68
8 (40) 105 (12) 0.001
6 (34) 310 (35) 0.63
4 (65) 637 (71) 0.001
6 (61) 327 (41) 0.001
0 (40) 326 (37) 0.07
4 (16) 145 (16) 0.72
1 (8) 137 (15) 0.001
3 (7) 109 (12) 0.001
1 (4) 57 (6) 0.004
6 (17) 157 (17) 0.87
61 11 61 11 0.11
2 (33) 242 (27) 0.001
8 (39) 347 (38)
1 (28) 315 (35)
30 5 29 4 0.001
30 19 137 20 0.001
75 11 73 11 0.001
4 (1, 12) 6 (2, 24) 0.009
3 (2, 7) 3 (1, 6) 0.001
7 (153, 204) 169 (145, 194) 0.001
8 (33, 46) 40 (34, 49) 0.001
2 (84, 126) 97 (78, 119) 0.002
8 (110, 225) 130 (96, 185) 0.001
2 (71, 94) 70 (60, 83) 0.001
es.
 congestive heart failure; CVD  cardiovascular disease; DBP  diastolic blood pressure; EF 
otein; MImyocardial infarction; PCI percutaneous coronary intervention; SBP systolic bloodAg
(n
1,19
1,18
54
45
88
76
55
21
11
9
5
23
46
53
38
1
17
3
10
15
8
ory valu
e; CHFerformed annually in the U.S. (11).
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The COURAGE Trial Outcomes by Age September 29, 2009:1303–8The American College of Cardiology (ACC)/AHA clinical
ractice guidelines for the treatment of ACS do not alter
herapeutic recommendations based on age, apart from en-
ouraging appropriate risk stratification, attention to comor-
idities, and appropriate dosing of medications (12,13). Alex-
nder et al. (2) demonstrated that the use of recommended
herapies in the elderly was significantly lower than in younger
atients in the 56,963 patient CRUSADE ACS (Evolution in
ardiovascular Care for Elderly Patients With Non–ST-
egment Elevation Acute Coronary Syndromes) registry. After
djustment for age-related differences in treatments, contrain-
ications, and comorbidities, elderly ACS patients were sig-
ificantly less likely to receive antiplatelet and antithrombin
herapy within the first 24 h, undergo early catheterization or
evascularization, and receive clopidogrel and statins at hospital
ischarge. Importantly, while in-hospital mortality and com-
aseline Characteristics by Treatment Assignment, Within Age GroTable 2 Baseline Characteristics by Treat ent Assignment, W
Age <65 Yrs
PCI  OMT
(n  688)
OMT
(n  693)
Demographic
Sex: male 599 (87) 598 (86)
Race: white 593 (86) 590 (85)
Age (yrs) 55 6 56 6
Risk factor
Current smoker 223 (32) 220 (32)
Diabetic patient 216 (31) 240 (35)
Hypertension 435 (63) 449 (65)
Family history of CAD 396 (58) 370 (53)
Cardiac history
MI 278 (40) 272 (39)
PCI 101 (15) 113 (16)
CABG 54 (8) 57 (8)
CVD 44 (6) 49 (7)
CHF 28 (4) 23 (3)
Angiographic
Low EF (50) 127 (19) 109 (16)
EF 60.7 11 60.6 10
1 VD 239 (35) 223 (32)
2 VD 264 (38) 274 (40)
3 VD 185 (27) 196 (28)
Physical
BMI 30 5 30 5
SBP 129 19 130 18
DBP 75 12 75 11
Angina*
Duration (months) 4 (1, 12) 4 (1, 12)
Episodes/week 4 (2, 7) 3 (1, 7)
Laboratory values*
Total cholesterol 175 (152, 204) 179 (154, 205)
HDL 38 (33, 46) 38 (32, 45)
LDL 102 (84, 126) 103 (85, 125)
Triglycerides 155 (110, 229) 162 (110, 229)
GFR 82 (71, 95) 81 (69, 93)
alues are n (%) or mean  SD. *Median and interquartile range is shown for angina and laborat
OMT  optimal medical therapy; other abbreviations as in Table 1.lication rates increased with advancing age, patients age 65 sears who received more ACC/AHA guideline-recommended
herapies had lower in-hospital mortality even after adjustment
han those who did not (2). Similar data from another large
nternational registry of patients with ACS with or without
T-segment elevation reported significantly decreased use of
ecommended therapies in the elderly (14). Thus, concordant
ndings from 2 ACS registries emphasize that even short-term
utcomes in the elderly may be favorably impacted by more
idespread use of proven secondary prevention therapies.
ittle evidence, however, is available regarding the potential
ong-term benefits associated with the use of evidence-based
edical therapies in older patients with stable ischemic heart
isease.
In the TIME (Trial of Invasive versus Medical Therapy
n Elderly patients) study, 1-year outcomes in elderly
atients with chronic angina were similar with regard to
Age Groups
p Value
Age >65 Yrs
p Value
PCI  OMT
(n  460)
OMT
(n  444)
0.67 380 (83) 370 (83) 0.77
0.58 395 (86) 385 (87) 0.71
0.06 72 5 72 5 0.91
0.43 37 (8) 39 (9) 0.76
0.27 151 (33) 159 (36) 0.32
0.62 322 (70) 315 (71) 0.74
172 (37) 155 (35)
0.72 159 (35) 167 (38) 0.33
0.41 73 (16) 72 (16)
0.80 70 (15) 67 (15) 0.96
0.62 56 (12) 53 (12) 0.91
0.46 29 (6) 28 (6) 0.99
0.17 82 (18) 75 (17) 0.72
0.84 61.3 11 61.5 10 0.74
0.59 121 (26) 120 (27) 0.74
82 (40) 165 (37)
56 (34) 159 (36)
0.99 28 4 29 5 0.60
0.29 138 21 136 20 0.93
0.40 73 12 73 11 0.49
0.66 5 (2, 24) 6 (2, 24) 0.19
0.19 3 (1, 6) 3 (1, 6) 0.51
0.15 166 (143, 190) 173 (147, 197) 0.04
0.71 40 (33, 49) 40 (34, 49) 0.94
0.79 96 (74, 116) 99 (80, 121) 0.15
0.14 129 (95, 185) 131 (99, 185) 0.48
0.06 71 (63, 84) 70 (58, 82) 0.18
es.upsithin
1
1ymptoms, quality of life, and death or nonfatal infarction
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September 29, 2009:1303–8 The COURAGE Trial Outcomes by Ageith invasive versus optimized medical strategies (15). In
table elderly patients (age 80 years) recovering from
T-segment elevation MI, Setoguchi et al. (16) showed a
0-year time trend in mortality improvement that was
ompletely abolished after adjustment for the use of statins,
eta-blockers, angiotensin inhibitors, and antiplatelet drugs,
ndicating that the more favorable outcome in long-term
ost-MI mortality was likely due to the increased use of
roven secondary prevention medications after discharge.
hile there was evidence that post-MI PCI procedures
ay have also contributed to improved survival, after
djusting for post-MI PCI procedural use during the index
I hospitalization, the temporal change associated with
mproved prognosis was largely attenuated. This suggests
hat, in post-MI patients, improved short-term outcomes
ay have been attributable to PCI, whereas evidence-based
econdary prevention therapies provided significant long-
erm prognostic benefit (17).
The results of the current COURAGE trial subset
nalysis provide important, new information on the clinical
enefit of OMT in a cohort of patients age 65 years who
ave chronic angina and stable CAD and who comprised
0% of all enrolled patients. OMT is remarkably effective in
chieving angina-free status during long-term follow-up,
ven acknowledging the expected reduction of physical
ctivity, which goes along with advanced age, and is as
ffective as PCI in reducing rates of death, MI, stroke, and
ngiographic/PCI Findings for Patients Randomized to PCI  OMTTable 3 Angiographic/PCI Findings for Patients Randomized to
Overall
Patients with procedure 1,072
Unable to cross 35
Not done 42
Patients with at least 1 stent 1,009
Lesions, measurable 1,666
Pre-PCI stenosis
Post-PCI stenosis
Stented lesions 1,448
Pre-PCI stenosis
Post-PCI stenosis
Angiographic success of attempted lesions 1,666
Clinical success 995
ngiographic success is defined as 20% stenosis in stented lesions, 50% in nonstented lesion
OMT  optical medical therapy; PCI  percutaneous coronary intervention.
rimary and Secondary Outcomes by Treatment Arm and Age GrouTable 4 Primary and Secondary Outcomes by Treatment Arm a
Age <65 Yrs (n  1,381)
Outcome
OMT
(n  693)
PCI
(n  688) HR (95% CI) p Val
Death 41 (6%) 25 (4%) 0.68 (0.42–1.10) 0.1
MI 76 (11%) 83 (12%) 1.12 (0.82–1.53) 0.4
Death/MI 110 (16%) 109 (16%) 1.01 (0.78–1.31) 0.9
Death/MI/stroke 115 (17%) 115 (17%) 1.02 (0.79–1.33) 0.8
ACS 85 (12%) 87 (13%) 1.03 (0.77–1.39) 0.8CS  acute coronary syndrome; CI  confidence interval; HR  hazard ratio; MI  myocardial infarctioospitalization for ACS. The present analysis demonstrates
hat not only can high rates of effective treatment be
chieved in older subjects with the use of aggressive phar-
acologic therapy and lifestyle intervention during long-
erm follow-up, but clinical events can be, likewise, favor-
bly impacted.
onclusions
MT is as effective in stable CAD patients age 65 years
s in patients age 65 years, and PCI, when added to
MT, does not reduce clinical events or improve angina
elief during long-term follow-up. While, as expected, older
atients have significantly higher overall rates of death and
he composite of death or MI than younger patients, our
esults demonstrate that the addition of PCI does not
itigate this risk. While it is also true that older patients
ndergoing PCI did not display higher event rates (as might
e anticipated in such patients with clinical comorbidities
uch as reduced kidney function), it nonetheless appears
ifficult to justify PCI as an initial treatment strategy in the
ajority of older patients with stable CAD, since clinical
utcomes (including angina relief) appeared similar in
MT-treated and PCI  OMT-treated patients. Thus,
hese data support continued adherence to the published
CC/AHA treatment guidelines, which endorse OMT as
 OMT
Age <65 Yrs Age >65 Yrs p Value
647 425
22 13
19 23
606 403
1,000 666
82.4 11.7 82.1 12.4 0.34
4.4 13.2 5.4 15.6 0.08
871 577
82.5 11.4 81.9 12.4 0.38
1.4 5.6 2.1 8.1 0.08
95.7 94.0 0.09
92.4 90.8 0.03
al success is defined as angiographic success in all lesions with no clinical complications.
e Group
Age >65 Yrs (n  904)
OMT
(n  444)
PCI
(n  460) HR (95% CI) p Value
Interaction
p Value
54 (12%) 57 (12%) 1.01 (0.69–1.46) 0.97 0.21
52 (12%) 60 (13%) 1.14 (0.79–1.66) 0.48 0.95
93 (21%) 104 (23%) 1.10 (0.83–1.45) 0.51 0.66
99 (22%) 109 (24%) 1.08 (0.82–1.42) 0.58 0.77
40 (9%) 49 (11%) 1.19 (0.79–1.81) 0.41 0.58PCIpnd Ag
ue
1
4
3
6
3n; other abbreviations as in Table 3.
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The COURAGE Trial Outcomes by Age September 29, 2009:1303–8he preferred initial management strategy for stable CAD
atients, regardless of age.
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